Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties.
about
New developments in the treatment of chronic lymphocytic leukemia: role of obinutuzumabNew antibody approaches to lymphoma therapyGlycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicityDaunorubicin-Loaded DNA Origami Nanostructures Circumvent Drug-Resistance Mechanisms in a Leukemia ModelOcaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemiaObinutuzumab: a novel anti-CD20 monoclonal antibody for previously untreated chronic lymphocytic leukemia.A phase II study of two dose levels of ofatumumab induction followed by maintenance therapy in symptomatic, previously untreated chronic lymphocytic leukemia.Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.Obinutuzumab: first global approval.Inhibition of autoimmune Chagas-like heart disease by bone marrow transplantationTargeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumabOncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia.Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study.Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia.Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphomaOfatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL).A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies.The role of chemotherapy in managing chronic lymphocytic leukemia: optimizing combinations with targeted therapy.CD30 as a therapeutic target for lymphoma.Ofatumumab as front-line therapy in untreated chronic lymphocytic leukemia.GA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is presentObinutuzumab: a review of its use in patients with chronic lymphocytic leukaemia.Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions.Microheterogeneity of therapeutic monoclonal antibodies is governed by changes in the surface charge of the protein.CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies.Ofatumumab: a novel, fully human anti-CD20 monoclonal antibody for the treatment of chronic lymphocytic leukemia.Regulatory myeloid cells: an underexplored continent in B-cell lymphomas.Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial results.Obinutuzumab (GA101) is highly effective against chronic lymphocytic leukemia cells in ex vivo B-cell depletion irrespective of high-risk prognostic markers.Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages.The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo.Assessment of structural and functional similarity of biosimilar products: Rituximab as a case study.Downregulation of CD3ζ in NK Cells from Systemic Lupus Erythematosus Patients Confers a Proinflammatory Phenotype.Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy.Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy.Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion
P2860
Q26801292-A002AE81-AD6A-46AC-A30D-D2EFC481C55DQ27022373-46D7AFE8-7A05-4BA3-A9BE-9DF8A09622AFQ28658712-5486F9ED-05F9-4534-9099-0E90048AEAF3Q28833494-D5CB4106-99CE-4F43-A176-597D4B62BA53Q30577607-923DBEA5-5850-48DB-8381-9C8559E41635Q33416524-3DE6A374-3232-4AF9-A39B-4EBEF34A1AE5Q33880538-98DFB9A1-C26C-47B6-959D-F96B935F9A4CQ34172063-4DE3D88E-DDF0-4C9D-B8BE-BFA62879BE97Q34391958-5671CF80-EC7F-4FA7-B163-767EF092890CQ34734088-50E7460B-F7ED-4F30-9445-5856F090F2C1Q35076449-70D15268-385E-4D4E-B692-8F73B8CF6E76Q35812675-940B8033-DB36-47BC-B438-29DB8A8EC115Q35953518-7C649F9C-C6A9-49C3-9058-E0C6315B58E9Q36443141-DC992517-C5D3-4408-BD66-41DA29AEFB48Q36897238-1339F715-89B0-4386-A6B3-6117A3C223C5Q37487919-C30CECDE-AACD-4020-91C6-9EB3EC28F8E1Q37672472-E5C4F3EF-F5F6-4D41-8602-63D444F1E304Q38126946-6A8ECB7E-4C76-48E7-8E10-4E8E5F9120CFQ38138482-17B1FE5C-0C5E-4B5C-8D84-01B972472D29Q38221686-75969FFE-6879-47FD-BD36-CF6F85DC42C9Q38315579-418DB061-C462-4319-86CB-A8E2FBDFE6CBQ38317353-1197EC02-8680-44F1-B95D-338BEF7880B3Q38542034-603D99F9-CC70-4F43-9F98-DAE78054517DQ38740314-ACFAE64A-0E19-4BB0-97CB-FD637885D1F2Q38807514-8280A729-2D6F-44D6-916B-E09D6C2E3F45Q39303346-BE677D1B-79B0-4155-BD90-842753AA71B9Q39423479-A90D8C1D-ABD9-4F59-98BA-5802CF7C3819Q41387926-3F772987-CE93-45C8-A807-81823D7ECDADQ42643066-D53B20DB-AC3C-45B6-B404-3F1573964798Q42660684-D988262F-CF82-4DB4-AAC9-E7B1B095965EQ49914090-B266AAAA-EDBE-4102-853C-2D481D39AD00Q50098437-8DD9D7E5-FF88-4C60-B8A4-5C8C4516D565Q52722794-2000DF53-EDD0-4195-8309-5504A9704717Q53151256-1546CD88-BC00-4CE0-9BC9-8C9F3734C395Q55283747-3FE262AA-0DDE-4AD1-81B3-9E243810832FQ58041703-1CC461CB-BFC8-4E23-A544-E8C451F55580
P2860
Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Comparative assessment of clin ...... te, and macrophage properties.
@en
Comparative assessment of clin ...... te, and macrophage properties.
@nl
type
label
Comparative assessment of clin ...... te, and macrophage properties.
@en
Comparative assessment of clin ...... te, and macrophage properties.
@nl
prefLabel
Comparative assessment of clin ...... te, and macrophage properties.
@en
Comparative assessment of clin ...... te, and macrophage properties.
@nl
P2093
P2860
P921
P356
P1476
Comparative assessment of clin ...... te, and macrophage properties.
@en
P2093
Carolyn Cheney
David Jarjoura
Jonathan P Butchar
Michael Caligiuri
Natarajan Muthusamy
Rossana Trotta
Susheela Tridandapani
Xiaokui Mo
P2860
P304
P356
10.4049/JIMMUNOL.1202588
P407
P577
2013-02-15T00:00:00Z